Aarkstore Hidradenitis Suppurativa – Pipeline Review, H1 2012

Document Sample
Aarkstore Hidradenitis Suppurativa – Pipeline Review, H1 2012 Powered By Docstoc
					Hidradenitis Suppurativa – Pipeline Review, H1 2012


Global Markets Direct’s, Hidradenitis Suppurativa Pipeline Review, H1 2012, provides an
overview of the Hidradenitis Suppurativa therapeutic pipeline. This report provides information
on the therapeutic development for Hidradenitis Suppurativa, complete with latest updates, and
special features on late-stage and discontinued projects. It also reviews key players involved in
the therapeutic development for Hidradenitis Suppurativa. Hidradenitis Suppurativa Pipeline
Review, H1 2012 is built using data and information sourced from Global Markets Direct’s
proprietary databases, Company/University websites, SEC filings, investor presentations and
featured press releases from company/university sites and industry-specific third party sources,
put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and
relevance of data for the indicated disease.


A snapshot of the global therapeutic scenario for Hidradenitis Suppurativa.
A review of the Hidradenitis Suppurativa products under development by companies and
universities/research institutes based on information derived from company and industry-specific
Coverage of products based on various stages of development ranging from discovery till
registration stages.
A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
Coverage of the Hidradenitis Suppurativa pipeline on the basis of route of administration and
molecule type.
Profiles of late-stage pipeline products featuring sections on product description, mechanism of
action and research & development progress.
Key discontinued pipeline projects.
Latest news and deals relating to the products.

Reasons to buy

Identify and understand important and diverse types of therapeutics under development for
Hidradenitis Suppurativa.
Identify emerging players with potentially strong product portfolio and design effective counter-
strategies to gain competitive advantage.
Plan mergers and acquisitions effectively by identifying players with the most promising
Devise corrective measures for pipeline projects by understanding Hidradenitis Suppurativa
pipeline depth and focus of Hidradenitis Suppurativa therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners
with the most attractive projects to enhance and expand business potential and scope.
Modify the therapeutic portfolio by identifying discontinued projects and understanding the
factors that drove them from pipeline.

For more information, please visit :-

Marketing Team

Aarkstore Enterprise


More Related Reports :-

Altitude Sickness (Acute mountain sickness) – Pipeline Review, H1 2012
Hidradenitis Suppurativa – Pipeline Review, H1 2012
Neisseriaceae Infections – Pipeline Review, H1 2012
Liver Failure – Pipeline Review, H1 2012
Small Intestine Cancer – Pipeline Review, H1 2012
Diabetic Foot Infection (DFI) – Pipeline Review, H1 2012
Lung Transplantation – Pipeline Review, H1 2012
HIV-Associated Lipodystrophy Syndrome – Pipeline Review, H1 2012
Angioedema – Pipeline Review, H1 2012
Community-Acquired Infections – Pipeline Review, H1 2012
Chronic Pancreatitis Pain – Pipeline Review, H1 2012
Tardive Dyskinesia – Pipeline Review, H1 2012

Description: Aarkstore announce a new report " Hidradenitis Suppurativa – Pipeline Review, H1 2012" through its vast collection of market research report